Loading publications…
The last 5 uploaded publications
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Gautier Stoll, Stefano Ugel, Ilaria Marigo, Shin Foong Ngiow, Aurélien Marabelle, Armelle Prévost‐Blondel, Pierre-Olivier Gaudreau, Vancheswaran Gopalakrishnan, Alexander Eggermont, Paule Opolon, Christophe Klein, Gabriele Madonna, Paolo A. Ascierto, Antje Sucker, Dirk Schadendorf, Mark J. Smyth, Jean‐Charles Soria, Guido Guido Kroemer, Vincenzo Bronte, Jennifer A. Wargo, Laurence Zitvogel, Nicolas Jacquelot, Takahiro Yamazaki, María P. Roberti, Connie P.M. Duong, Miles C. Andrews, Loïc Verlingue, Gladys Ferrere, Sonia Becharef, Marie Vétizou, Romain Daillère, Meriem Messaoudene, David Enot (2019). Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. , 29(10), DOI: https://doi.org/10.1038/s41422-019-0224-x.
Article72 days agoDefining the critical hurdles in cancer immunotherapy
Bernard A. Fox, Dolores J. Schendel, Lisa H. Butterfield, Steinar Aamdal, James P. Allison, Paolo A. Ascierto, Michael B. Atkins, Jiřina Bartůňková, Lothar Bergmann, Neil L. Berinstein, Cristina C Bonorino, Ernest C. Borden, Jonathan L. Bramson, Cedrik M. Britten, Xuetao Cao, William E. Carson, Alfred E. Chang, Dainius Characiejus, Aniruddha Choudhury, George Coukos, Tanja D. de Gruijl, Robert O. Dillman, Harry Dolstra, Glenn Dranoff, Lindy G. Durrant, James H. Finke, Jérôme Galon, Jared Gollob, Cécile Gouttefangeas, Fabio Grizzi, Michele Guida, Leif Håkansson, Kristen Hege, Ronald B. Herberman, F. Stephen Hodi, Axel Hoos, Christoph Huber, Patrick Hwu, Kohzoh Imai, Elizabeth M. Jaffee, Sylvia Janetzki, Carl H. June, Paweł Kaliński, Howard L. Kaufman, Koji Kawakami, Yutaka Kawakami, Ulrich Keilholtz, Samir N. Khleif, Rolf Kiessling, Beatrix Kotlán, Guido Guido Kroemer, Réjean Lapointe, Hyam I. Levitsky, Michael T. Lotze, Cristina Maccalli, Michele Maio, Jens‐Peter Marschner, Michael J. Mastrangelo, Giuseppe Masucci, Ignacio Melero, C.J.M. Melief, William J. Murphy, Brad H. Nelson, Andrea Nicolini, Michael I. Nishimura, Kunle Odunsi, Pamela S. Ohashi, Jill O’Donnell-Tormey, Lloyd J. Old, Christian H. Ottensmeier, Michael Papamichail, Giorgio Parmiani, Graham Pawelec, Enrico Proietti, Shukui Qin, Robert C. Rees, Antoni Ribas, Ruggero Ridolfi, Gerd Ritter, Licia Rivoltini, Pedro Romero, Mohamed L. Salem, Rik J. Scheper, Barbara Seliger, Padmanee Sharma, Hiroshi Shiku, Harpreet Singh‐Jasuja, Wenru Song, Per thor Straten, Hideaki Tahara, Zhigang Tian, Sjoerd H. van der Burg, Paul von Hoegen, Ena Wang, Marij J.P. Welters, H. Winter, Tara Withington, Jedd D. Wolchok, Weihua Xiao, Laurence Zitvogel (2011). Defining the critical hurdles in cancer immunotherapy. , 9(1), DOI: https://doi.org/10.1186/1479-5876-9-214.
Editorial material72 days agoFigure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221276.
Preprint62 days agoDurability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. , 183, DOI: https://doi.org/10.1016/j.ejca.2023.01.016.
Article62 days agoTable 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221270.
Preprint62 days ago